AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20389159 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus, mycophenolate mofetil, and steroids (Group B)
Number of subjects: 24
Study 18336747 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament polypropylene mesh
Number of subjects: 32
Study 18336747 — intervention group
Group type: COMPARATOR
Intervention: Multifilament polypropylene mesh
Number of subjects: 32
Study 15632669 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with the exercise assist device
Number of subjects: 15
Study 15632669 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at approximately 60% VO(2max)
Number of subjects: 15
Study 15632669 — intervention group
Group type: COMPARATOR
Intervention: Sitting
Number of subjects: 15
Study 12457449 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-fortified salt (iodine 25 microg/g salt and iron 1 mg/g salt)
Number of subjects: 377
Study 12457449 — intervention group
Group type: COMPARATOR
Intervention: Iodized salt (25 microg iodine/g salt)
Number of subjects: 377
Study 10334396 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with brainstem lesions
Number of subjects: 3
Study 10334396 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 8596499 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RE)
Number of subjects: 15
Study 8596499 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RE) + recombinant human growth hormone (rhGH)
Number of subjects: 15
Study 8596499 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RE) + rhGH
Number of subjects: 15
Study 8596499 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RE) or hormone treatment
Number of subjects: 15
Study 1749302 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with folinic acid, 5-Fluorouracil (FU) and mitomycin C (MMC)
Number of subjects: 96
Study 1749302 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 96
Study 7044606 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 686
Study 7044606 — intervention group
Group type: COMPARATOR
Intervention: Control (Medical treatment)
Number of subjects: 686
Study 30817778 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL at Day 1
Number of subjects: 225
Study 30817778 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed urine output
Number of subjects: 225
Study 30817778 — intervention group
Group type: EXPERIMENTAL
Intervention: All biomarkers measured at Day 1 (except urinary L-FABP)
Number of subjects: 225
Study 30817778 — intervention group
Group type: EXPERIMENTAL
Intervention: Early biomarker levels
Number of subjects: 225
Study 28183345 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted Single-Site™ cholecystectomy
Number of subjects: 60
Study 28183345 — intervention group
Group type: COMPARATOR
Intervention: Single-incision laparoscopic cholecystectomy
Number of subjects: 60
Study 26341963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis derivatives
Number of subjects: 0
Study 26341963 — intervention group
Group type: EXPERIMENTAL
Intervention: Botanicals with anticonvulsant properties
Number of subjects: 0
Study 23351826 — intervention group
Group type: EXPERIMENTAL
Intervention: Aborted myocardial infarction (AbMI)
Number of subjects: 5745
Study 23351826 — intervention group
Group type: EXPERIMENTAL
Intervention: AbMI
Number of subjects: 5745
Study 21308609 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic sodium chloride solution (3% NaCl)
Number of subjects: 20
Study 21308609 — intervention group
Group type: COMPARATOR
Intervention: Isotonic salt solution (0.9% NaCl)
Number of subjects: 20
Study 19084860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined perianal‐intrarectal lidocaine‐prilocaine cream and periprostatic nerve block (group 1)
Number of subjects: 280
Study 19084860 — intervention group
Group type: EXPERIMENTAL
Intervention: Perianal‐intrarectal lidocaine‐prilocaine cream alone (group 2)
Number of subjects: 280
Study 19084860 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block alone (group 3)
Number of subjects: 280
Study 19084860 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia (group 4)
Number of subjects: 280
Study 17463297 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium beverage (164 mmol Na(+)/l)
Number of subjects: 13
Study 17463297 — intervention group
Group type: COMPARATOR
Intervention: Low sodium beverage (10 mmol Na(+)/l)
Number of subjects: 13
Study 17463297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium loading (High Na(+))
Number of subjects: 13
Study 15353052 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotape of GP consultation
Number of subjects: 180
Study 15353052 — intervention group
Group type: COMPARATOR
Intervention: Control group (no audiotape)
Number of subjects: 180
Study 11786670 — intervention group
Group type: EXPERIMENTAL
Intervention: Various methods of evaluation (direct symptom outcomes, cumulative frequency distribution of threshold improvements, linear regression analysis of individual IPSS)
Number of subjects: 0
Study 11786670 — intervention group
Group type: COMPARATOR
Intervention: Standard RCT methods (percentage of Symptom Index improvement)
Number of subjects: 0
Study 9511777 — intervention group
Group type: EXPERIMENTAL
Intervention: Whirlpool bath at 40°C
Number of subjects: 6
Study 9511777 — intervention group
Group type: COMPARATOR
Intervention: User-controlled water temperature (UCT)
Number of subjects: 6
Study 7862806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively oriented pretreatment intervention
Number of subjects: 48
Study 7862806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study 2074425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device (Enac) at power level 1
Number of subjects: 60
Study 2074425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device (Enac) at power level 2
Number of subjects: 60
Study 2074425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device (Enac) at power level 3
Number of subjects: 60
Study 2074425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device (Enac) at power level 5
Number of subjects: 60
Study 2074425 — intervention group
Group type: COMPARATOR
Intervention: Hand instrumentation (Group E)
Number of subjects: 60
Study 2074425 — intervention group
Group type: COMPARATOR
Intervention: Uninstrumented controls (Group F)
Number of subjects: 60
Study 7372352 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol alone (P)
Number of subjects: 367
Study 7372352 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus hydrochlorothiazide (P + T)
Number of subjects: 367
Study 7372352 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus hydralazine (P + H)
Number of subjects: 367
Study 7372352 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine plus hydrochlorothiazide (R + T)
Number of subjects: 367
Study 7372352 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus hydrochlorothiazide plus hydralazine (P + T + H)
Number of subjects: 367
Study 31361714 — intervention group
Group type: EXPERIMENTAL
Intervention: PA sedentary reduction (PASR) group
Number of subjects: 38
Study 31361714 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC) group
Number of subjects: 38
Study 31397121 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming acupuncture combined with moxibustion at Yongquan (KI 1)
Number of subjects: 66
Study 31397121 — intervention group
Group type: COMPARATOR
Intervention: Simple warming acupuncture
Number of subjects: 66
Study 28860046 — intervention group
Group type: EXPERIMENTAL
Intervention: IVB (2.5 mg/0.1 mL) administered 5-10 days before PPV (Group B)
Number of subjects: 156
Study 28860046 — intervention group
Group type: COMPARATOR
Intervention: IVB (2.5 mg/0.1 mL) administered 1-3 days before PPV (Group A)
Number of subjects: 156
Study 26448030 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISBPB)
Number of subjects: 93
Study 26448030 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular brachial plexus block (SCBPB)
Number of subjects: 93
Study 23347722 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 94
Study 23347722 — intervention group
Group type: EXPERIMENTAL
Intervention: AirTraq
Number of subjects: 94
Study 23347722 — intervention group
Group type: EXPERIMENTAL
Intervention: King LTS-D
Number of subjects: 94
Study 23347722 — intervention group
Group type: EXPERIMENTAL
Intervention: GVL
Number of subjects: 94
Study 23347722 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAC
Number of subjects: 94
Study 22939034 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily
Number of subjects: 245
Study 22939034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 18581160 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass plus laser irradiation (40 mW, 4 J/cm², total energy density 16 J/cm²)
Number of subjects: 20
Study 18581160 — intervention group
Group type: COMPARATOR
Intervention: Bioactive glass only
Number of subjects: 20
Study 17535636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional remedy with the dipeptide of glutamine and alanine (Group G)
Number of subjects: 46
Study 17535636 — intervention group
Group type: COMPARATOR
Intervention: Routine nutritional therapy only (Group C)
Number of subjects: 46
Study 15070913 — intervention group
Group type: EXPERIMENTAL
Intervention: 20K-hGH 0.006 mg/kg.d
Number of subjects: 55
Study 15070913 — intervention group
Group type: EXPERIMENTAL
Intervention: 20K-hGH 0.012 mg/kg.d
Number of subjects: 55
Study 15070913 — intervention group
Group type: EXPERIMENTAL
Intervention: 20K-hGH 0.024 mg/kg.d
Number of subjects: 55
Study 11472043 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive therapy
Number of subjects: 253
Study 11472043 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical training
Number of subjects: 253
Study 11472043 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 253
Study 9428488 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT) including excisional biopsy and postoperative external beam irradiation (45-50 Gy to the whole breast and a boost to the tumor bed to at least 60 Gy)
Number of subjects: 400
Study 7527508 — intervention group
Group type: EXPERIMENTAL
Intervention: cICAM-1 levels in active MS patients
Number of subjects: 29
Study 7527508 — intervention group
Group type: EXPERIMENTAL
Intervention: cICAM-1 levels at relapse
Number of subjects: 29
Study 7527508 — intervention group
Group type: EXPERIMENTAL
Intervention: cTNF-R p60 levels in stable MS patients
Number of subjects: 29
Study 7527508 — intervention group
Group type: EXPERIMENTAL
Intervention: cTNF-R p60 levels at relapse
Number of subjects: 29
Study 7527508 — intervention group
Group type: EXPERIMENTAL
Intervention: cL-selectin levels in MS patients
Number of subjects: 29
Study 2644999 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 170
Study 2644999 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 170
Study 2644999 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 170
Study 799976 — intervention group
Group type: EXPERIMENTAL
Intervention: Halcinonide
Number of subjects: 0
Study 799976 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate
Number of subjects: 0
Study 30225852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lime powder regimen (LPR)
Number of subjects: 74
Study 30225852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 28158558 — intervention group
Group type: EXPERIMENTAL
Intervention: Step Care intervention (single counseling session, nicotine patch for six weeks, telephonic contact)
Number of subjects: 270
Study 28158558 — intervention group
Group type: COMPARATOR
Intervention: Recycle intervention (one session of health behavior counseling, nicotine patch for six weeks, telephone call at each step)
Number of subjects: 270
Study 23828089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenotomy
Number of subjects: 151
Study 23828089 — intervention group
Group type: COMPARATOR
Intervention: Tenodesis
Number of subjects: 151
Study 23413062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile device (Apple fourth-generation iPod Touch)
Number of subjects: 93
Study 23413062 — intervention group
Group type: COMPARATOR
Intervention: Computer monitor (23-inch LCD)
Number of subjects: 93
Study 21334613 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH (50‐150 IU/d) plus ganirelix (0.25 mg/d)
Number of subjects: 93
Study 21334613 — intervention group
Group type: COMPARATOR
Intervention: recombinant FSH (50‐150 IU/d) only
Number of subjects: 93
Study 19860071 — intervention group
Group type: EXPERIMENTAL
Intervention: socioculturally adapted collaborative care depression management intervention
Number of subjects: 387
Study 19860071 — intervention group
Group type: COMPARATOR
Intervention: not available
Number of subjects: 387
Study 16951690 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (5 microg/kg/day)
Number of subjects: 103
Study 16951690 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (5 microg/kg/day)
Number of subjects: 103
Study 16951690 — intervention group
Group type: EXPERIMENTAL
Intervention: Molgramostim (5 microg/kg/day)
Number of subjects: 103
Study 14755132 — intervention group
Group type: EXPERIMENTAL
Intervention: lamotrigine (300 mg per os)
Number of subjects: 19
Study 14755132 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 11389707 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin 20 mg/d
Number of subjects: 65
Study 11389707 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 65
Study 9268795 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 105
Study 9268795 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate (5 mg)
Number of subjects: 105
Study 9268795 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (50 mg)
Number of subjects: 105
Study 9268795 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine sulfate and bupivacaine
Number of subjects: 105
Study 8299668 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically deposited frusemide (F) 10(-4) M
Number of subjects: 7
Study 8299668 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically deposited frusemide (F) 10(-3) M
Number of subjects: 7
Study 8299668 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically deposited amiloride (A) 10(-5) M
Number of subjects: 7
Study 8299668 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically deposited amiloride (A) 10(-4) M
Number of subjects: 7
Study 8299668 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically deposited amiloride (A) 10(-3) M
Number of subjects: 7
Study 8299668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised amiloride (A) 10(-2) M
Number of subjects: 7
Study 8299668 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically deposited frusemide (F) and amiloride (A) 10(-3) M
Number of subjects: 7
Study 8299668 — intervention group
Group type: COMPARATOR
Intervention: Inhaled frusemide (F)
Number of subjects: 7
Study 8299668 — intervention group
Group type: COMPARATOR
Intervention: Inhaled bumetanide (B)
Number of subjects: 7
Study 8299668 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol (S)
Number of subjects: 7
Study 8299668 — intervention group
Group type: COMPARATOR
Intervention: Topically deposited bumetanide (B)
Number of subjects: 7
Study 8299668 — intervention group
Group type: COMPARATOR
Intervention: Topically deposited salbutamol (S)
Number of subjects: 7
Study 3333529 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 8
Study 3333529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31641769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime hypertension treatment (n=9552)
Number of subjects: 19084
Study 31641769 — intervention group
Group type: COMPARATOR
Intervention: Upon awakening hypertension treatment (n=9532)
Number of subjects: 19084
Study 28758192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg subcutaneously once every 2 weeks (Q2W)
Number of subjects: 0
Study 28758192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26888985 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early and frequent mobilization, commencing within 24 hours
Number of subjects: 2104
Study 26888985 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2104
Study 24915873 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of CD8+ T cells within the tumour in ER-negative tumours
Number of subjects: 12439
Study 24915873 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of CD8+ T cells within the stroma in ER-negative tumours
Number of subjects: 12439
Study 24915873 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of CD8+ T cells within the tumour in ER-positive HER2-positive tumours
Number of subjects: 12439
Study 24915873 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ tumours in ER-negative disease receiving anthracyclines
Number of subjects: 12439
Study 24915873 — intervention group
Group type: COMPARATOR
Intervention: CD8-negative tumours in ER-negative disease receiving anthracyclines
Number of subjects: 12439
Study 22643725 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential light therapy with two independent cluster probes (n = 15)
Number of subjects: 30
Study 22643725 — intervention group
Group type: COMPARATOR
Intervention: Conventional light therapy with one active probe (n = 15)
Number of subjects: 30
Study 20493486 — intervention group
Group type: EXPERIMENTAL
Intervention: R-scope (prototype endoscope with two deflecting working channels)
Number of subjects: 0
Study 20493486 — intervention group
Group type: COMPARATOR
Intervention: Conventional double-channel endoscope
Number of subjects: 0
Study 18546536 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam combined with fentanyl
Number of subjects: 80
Study 18546536 — intervention group
Group type: COMPARATOR
Intervention: Propofol combined with fentanyl
Number of subjects: 80
Study 15752103 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/fluoride (TCF-AF) dentifrice
Number of subjects: 0
Study 15752103 — intervention group
Group type: COMPARATOR
Intervention: Commercially available breath freshening (CBF) dentifrice
Number of subjects: 0
Study 12508047 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal adaptation evaluation using modified USPHS criteria
Number of subjects: 435
Study 12508047 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal adaptation evaluation excluding steps with a height greater or less than one standard deviation of the mean
Number of subjects: 435
Study 12508047 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal height boundary for marginal adaptation
Number of subjects: 435
Study 10639529 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg mexiletine
Number of subjects: 14
Study 10639529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8628358 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 inhibitor (25 plasma units per kilogram of body weight)
Number of subjects: 17
Study 8628358 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 inhibitor (25 plasma units per kilogram)
Number of subjects: 17
Study 8628358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1324529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) products
Number of subjects: 0
Study 6711955 — intervention group
Group type: COMPARATOR
Intervention: Castrated (group 2)
Number of subjects: 18
Study 6711955 — intervention group
Group type: EXPERIMENTAL
Intervention: Castrated with testosterone (group 3)
Number of subjects: 18
Study 6711955 — intervention group
Group type: COMPARATOR
Intervention: Intact controls (group 1)
Number of subjects: 18
Study 30764736 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise
Number of subjects: 8
Study 30764736 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Number of subjects: 8
Study 30764736 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOO supplementation
Number of subjects: 8
Study 29953547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (TFV) IVR
Number of subjects: 51
Study 29953547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir plus Levonorgestrel (TFV/LNG) IVR
Number of subjects: 51
Study 29953547 — intervention group
Group type: COMPARATOR
Intervention: Placebo IVR
Number of subjects: 51
Study 26558434 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine oral solution 0.5 mg/mL
Number of subjects: 13
Study 26558434 — intervention group
Group type: COMPARATOR
Intervention: Norvasc® 5 mg tablets
Number of subjects: 13
Study 26558434 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 13
Study 25011980 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic and planned GP intervention
Number of subjects: 3245
Study 25011980 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 3245
Study 22127561 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic sodium bicarbonate infusion
Number of subjects: 11
Study 22127561 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (isotonic saline)
Number of subjects: 11
Study 22127561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trials (Isotonic sodium bicarbonate infusion and Placebo infusion)
Number of subjects: 11
Study 19690833 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel-rise work test
Number of subjects: 78
Study 17875200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal bran flakes
Number of subjects: 12
Study 17875200 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholemeal oat flakes
Number of subjects: 12
Study 17875200 — intervention group
Group type: COMPARATOR
Intervention: Corn flakes
Number of subjects: 12
Study 15827359 — intervention group
Group type: EXPERIMENTAL
Intervention: Self videotape feedback
Number of subjects: 70
Study 15827359 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of expert and self videotape feedback
Number of subjects: 70